Increased serum PAI-1 levels in subjects with metabolic syndrome and long-term adverse mental symptoms: A population-based study

Cardiovascular Psychiatry and Neurology

Volumn , Issue , 2010, Pages

  Huotari, Anne ^a   Lehto, Soili M ^b,c   Niskanen, Leo ^b   Herzig, Karl Heinz ^a,b   Hintikka, Jukka ^b   Koivumaa Honkanen, Heli ^a   Tolmunen, Tommi ^b   Honkalampi, Kirsi ^c   Kaikkonen, Noora ^b   Viinamki, Heimo ^b  

^a UNIVERSITY OF OULU   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Kuopio Psychiatric Center   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR;

EID: 77955956662     PISSN: 20900163     EISSN: 20900171     Source Type: Journal    
DOI: 10.1155/2010/501349     Document Type: Article

References (43)

1. Viinamki H., Heiskanen T., Lehto S. M., Association of depressive symptoms and metabolic syndrome in men Acta Psychiatrica Scandinavica 2009 120 23 29
2. Glassman A. H., Shapiro P. A., Depression and the course of coronary artery disease American Journal of Psychiatry 1998 155 1 4 11
3. Rikknen K., Matthews K. A., Kuller L. H., The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism: Clinical and Experimental 2002 51 12 1573 1577
4. Carney R. M., Freedland K. E., Miller G. E., Jaffe A. S., Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms Journal of Psychosomatic Research 2002 53 4 897 902
5. Berg A. H., Scherer P. E., Adipose tissue, inflammation, and cardiovascular disease Circulation Research 2005 96 9 939 949
6. Tsai S.-J., The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression Medical Hypotheses 2005 66 2 319 322
7. Koponen H., Jokelainen J., Keinanen-Kiukaanniemi S., Kumpusalo E., Vanhala M., Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study Journal of Clinical Psychiatry 2008 69 2 178 182
8. Binder B. R., Christ G., Gruber F., Plasminogen activator inhibitor 1: physiological and pathophysiological roles News in Physiological Sciences 2002 17 2 56 61
9. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., Arner P., Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals Diabetologia 1998 41 1 65 71
10. Kooistra T., Sprengers E. D., van Hinsbergh V. W. M., Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells Biochemical Journal 1986 239 3 497 503
11. Vaughan D. E., PAI-1 and atherothrombosis Journal of Thrombosis and Haemostasis 2005 3 8 1879 1883
12. Rao J. S., Chen M., Festoff B. W., Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid Journal of Neuroscience Research 1993 34 3 340 345
13. Benchenane K., Berezowski V., Ali C., Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis Circulation 2005 111 17 2241 2249
14. Melchor J. P., Strickland S., Tissue plasminogen activator in central nervous system physiology and pathology Thrombosis and Haemostasis 2005 93 4 655 660
15. Yepes M., Sandkvist M., Moore E. G., Bugge T. H., Strickland D. K., Lawrence D. A., Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein Journal of Clinical Investigation 2003 112 10 1533 1540
16. Hino H., Akiyama H., Iseki E., Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues Neuroscience Letters 2001 297 2 105 108
17. Eskandari F., Mistry S., Martinez P. E., Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk Metabolism: Clinical and Experimental 2005 54 7 918 924
18. Lahlou-Laforet K., Alhenc-Gelas M., Pornin M., Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease American Journal of Cardiology 2006 97 9 1287 1291
19. Lehto S. M., Niskanen L., Herzig K.-H., Serum chemokine levels in major depressive disorder Psychoneuroendocrinology 2010 35 2 226 232
20. Lehto S. M., Huotari A., Niskanen L., Serum adiponectin and resistin levels in major depressive disorder Acta Psychiatrica Scandinavica 2010 121 3 209 215
21. Beck A. T., Ward C. H., Mendelson M., Mock J., Erbaugh J., An inventory for measuring depression Archives of General Psychiatry 1961 4 561 571
22. Joukamaa M., Miettunen J., Kokkonen P., Psychometric properties of the Finnish 20-item Toronto Alexithymia Scale Nordic Journal of Psychiatry 2001 55 2 123 127
23. Koivumaa-Honkanen H., Honkanen R., Viinamki H., Heikkil K., Kaprio J., Koskenvuo M., Self-reported life satisfaction and 20-year mortality in healthy finnish adults American Journal of Epidemiology 2000 152 10 983 991
24. Yamamoto K., Takeshita K., Kojima T., Takamatsu J., Saito H., Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovascular Research 2005 66 2 276 285
25. Matthews K. A., Schott L. L., Bromberger J., Cyranowski J., Everson-Rose S. A., Sowers M. F., Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition Psychosomatic Medicine 2007 69 2 124 130
26. von Kanel R., Maly F. E., Frey K., Fischer J. E., Contribution of the type 1 plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis in vital exhaustion Italian Heart Journal 2003 4 11 791 796
27. Kop W. J., Hamulyak K., Pernot C., Appels A., Relationship of blood coagulation and fibrinolysis to vital exhaustion Psychosomatic Medicine 1998 60 3 352 358
28. Raikkonen K., Lassila R., Keltikangas-Jarvinen L., Hautanen A., Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 3 363 367
29. Geiser F., Meier C., Wegener I., Association between anxiety and factors of coagulation and fibrinolysis Psychotherapy and Psychosomatics 2008 77 6 377 383
30. Tsai S.-J., Hong C.-J., Liou Y.-J., Yu Y. W.-Y., Chen T.-J., Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response Pharmacogenetics and Genomics 2008 18 10 869 875
31. Hou S.-J., Yen F.-C., Tsai S.-J., Is dysfunction of the tissue plasminogen activator (tPA)-plasmin pathway a link between major depression and cardiovascular disease? Medical Hypotheses 2009 72 2 166 168
32. Pietraszek M. H., Takada Y., Nishimoto M., Ohara K., Ohara K., Takada A., Fibrinolytic activity in depression and neurosis Thrombosis Research 1991 63 6 661 666
33. Monteleone P., Serritella C., Martiadis V., Maj M., Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders Bipolar Disorders 2008 10 1 95 100
34. Akenami F. O. T., Koskiniemi M., Farkkila M., Vaheri A., Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease Journal of Clinical Pathology 1997 50 2 157 160
35. Wang L., Rockwood J., Zak D., Devaraj S., Jialal I., Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome Metabolic Syndrome and Related Disorders 2008 6 2 149 152
36. Qu H.-Y., Xiao Y.-W., Jiang G.-H., Wang Z.-Y., Zhang Y., Zhang M., Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia Pharmaceutical Research 2009 26 4 958 964
37. Young-Xu Y., Chan K. A., Liao J. K., Ravid S., Blatt C. M., Long-term statin use and psychological well-being Journal of the American College of Cardiology 2003 42 4 690 697
38. Mertens I., Verrijken A., Michiels J. J., van der Planken M., Ruige J. B., Van Gaal L. F., Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome International Journal of Obesity 2006 30 8 1308 1314
39. Asselbergs F. W., Williams S. M., Hebert P. R., Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits Journal of Thrombosis and Haemostasis 2007 5 2 313 320
40. Gebara O. C. E., Mittleman M. A., Sutherland P., Association between increased estrogen status and increased fibrinolytic potential in the framingham offspring study Circulation 1995 91 7 1952 1958
41. Linkov F., Gu Y., Arslan A. A., Reliability of tumor markers, chemokines, and metastasis-related molecules in serum European Cytokine Network 2009 20 1 21 26
42. Merikangas K. R., Zhang H., Avenevoli S., Acharyya S., Neuenschwander M., Angst J., Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study Archives of General Psychiatry 2003 60 10 993 1000
43. Tuttolomondo A., Pinto A., Corrao S., Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis Atherosclerosis 2009 203 2 503 508